Dermata Therapeutics (DRMA) director receives 2,500 stock options

Rhea-AI Filing Summary

Dermata Therapeutics director David F. Hale reported a new stock option grant. On 01/02/2026, he was awarded a stock option to buy 2,500 shares of Dermata Therapeutics, Inc. common stock at an exercise price of $2.18 per share.

The option vests in twelve substantially equal monthly installments, with the first installment vesting one month after the grant date, as long as he remains in continuous service through each vesting date. Following this grant, he beneficially owns 2,500 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HALE DAVID F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HALE DAVID F

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD., #322

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.18	01/02/2026		A		2,500		(1)	01/01/2036	Common Stock	2,500	$0	2,500	D

Explanation of Responses:

1. The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.

	/s/ Gerald T. Proehl, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report on this Form 4?

The filing reports that director David F. Hale received a grant of a stock option (right to buy) for 2,500 shares of Dermata Therapeutics, Inc. common stock.

On what date was the stock option granted to David F. Hale at Dermata Therapeutics (DRMA)?

The stock option was granted on 01/02/2026, which is listed as the earliest transaction date in the filing.

What is the exercise price of the Dermata Therapeutics (DRMA) stock option granted to David F. Hale?

The option has an exercise price of $2.18 per share for the underlying Dermata Therapeutics, Inc. common stock.

How many Dermata Therapeutics (DRMA) shares are covered by David F. Hale’s new stock option?

The stock option covers 2,500 shares of Dermata Therapeutics, Inc. common stock.

How does the Dermata Therapeutics (DRMA) stock option granted to David F. Hale vest?

The shares underlying the option vest in twelve successive substantially equal monthly installments, starting one month after the grant date, subject to his continuous service through each vesting date.

What is David F. Hale’s ownership form for the reported Dermata Therapeutics (DRMA) derivative securities?

The 2,500 stock options are reported as being held with direct (D) ownership.